Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 7 sources
Summary
Ulixacaltamide is an investigational oral treatment for adults with essential tremor. The phase 3 regimen was 60 mg once daily after titration. Supporting evidence includes treatment alongside stable propranolol, but these data do not establish superiority to propranolol or primidone. The available pivotal studies compare ulixacaltamide with placebo, including withdrawal of treatment in selected responders. Routine use and final prescribing conditions remain dependent on regulatory review. The manufacturer reports an established distribution network; expanded-access requests must come from the treating physician and are considered individually.